Epic Sciences, Abramson Cancer Center partnership, 2/16

Epic Sciences announced a collaboration with University of Pennsylvania’s Abramson Cancer Center on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells at a single cell resolution, that are predictive of response to personalized cancer therapeutics.

Epic Sciences’ “No cell left behind” CTC detection and characterization platform is used to quantify the proteomic and genomic changes that accumulate in tumor cells over time and in response to successive rounds of therapy. The platform can detect all categories of CTCs in the blood and identify, on a single cell basis, subpopulations of metastatic cancer cells that may be resistant or susceptible to cancer therapeutics. The platform has an unbiased detection approach in which all nucleated cells are analyzed.

The research teams at the Abramson Cancer Center will use Epic Sciences’ CTC detection and analysis platform to explore the heterogeneity of a diversity of cancer types, with a focus on genomic and phenotypic markers that help to better understand the utility of existing therapies and potential new drugs.
Epic Sciences,

Epic Sciences , 858-356-6610